Why Bausch Health Companies Shares Are Falling After Q1 Results
Why Bausch Health Companies Shares Are Falling After Q1 Results
Bausch Health Companies Inc. (NYSE:BHC) shares are trading lower on Thursday after reporting first-quarter results.
鮑什健康公司（紐約證券交易所代碼：BHC）在公佈第一季度業績後，股價週四走低。
The company reported adjusted quarterly earnings per share of 59 cents, missing the street view of 72 cents.
該公司報告調整後的每股季度收益爲59美分，低於72美分的街景。
Sales of $2.153 billion marginally missed the analyst consensus of $2.156 billion. Sales increased 11% on a reported basis and 8% on an organic basis.
21.53億美元的銷售額略低於分析師共識的21.56億美元。報告的銷售額增長了11％，有機銷售額增長了8％。
Segment Details: Bausch + Lomb segment reported revenues were $1.099 billion for the first quarter of 2024, compared with $931 million for the first quarter of 2023, an increase of $168 million, or 18%.
細分市場詳情：Bausch + Lomb板塊報告稱，2024年第一季度的收入爲10.99億美元，而2023年第一季度爲9.31億美元，增長1.68億美元，增長18％。
Salix segment reported revenues were $499 million, up 1% year over year.
Salix板塊公佈的收入爲4.99億美元，同比增長1％。
The International segment reported revenues were $265 million, compared with $247 million for the first quarter of 2023, an increase of 7%.
國際板塊報告的收入爲2.65億美元，而2023年第一季度爲2.47億美元，增長了7％。
Solta Medical segment reported revenues were $88 million, up 21% year over year.
Solta Medical板塊公佈的收入爲8,800萬美元，同比增長21％。
Diversified segment reported revenues were $202 million, an increase of 3% year over year.
多元化細分市場報告的收入爲2.02億美元，同比增長3％。
Bausch Health Companies reported first quarter adjusted EBITDA of $665 million, up 13% year over year.
Bausch Health Companies報告稱，第一季度調整後的息稅折舊攤銷前利潤爲6.65億美元，同比增長13％。
"We are also pleased with other key developments for our business during the quarter, including the appeal decision in the Norwich matter in respect of Xifaxan, which represents a significant milestone as it relates to achieving the full separation of Bausch + Lomb," said Thomas J. Appio, Chief Executive Officer, Bausch Health.
Bausch Health首席執行官托馬斯·阿皮奧表示：“我們還對本季度業務的其他關鍵進展感到滿意，包括諾里奇案中有關Xifaxan的上訴裁決，這是一個重要的里程碑，因爲它與實現Bausch + Lomb的完全分離有關。”
The company generated $211 million of cash from operating activities in the first quarter of 2024. Bausch Health Companies exited the first quarter with cash and equivalents worth $755 million.
該公司在2024年第一季度通過經營活動產生了2.11億美元的現金。Bausch Health Companies以價值7.55億美元的現金及等價物在第一季度退出。
Outlook: Bausch Health Companies reaffirmed 2024 revenues of $9.3 billion-$9.55 billion versus consensus of $9.39 billion. The company projects an adjusted EBITDA of $3.20 billion-$3.35 billion.
展望：Bausch Health Companies重申2024年的收入爲93億至95.5億美元，而預期收入爲93.9億美元。該公司預計，調整後的息稅折舊攤銷前利潤爲32.0億美元至33.5億美元。
Price Action: BHC shares are trading lower by 7.37% to $8.105 at last check Thursday.
價格走勢：在週四的最後一次檢查中，BHC股價下跌7.37％，至8.105美元。
譯文內容由第三人軟體翻譯。